Haoxi Health Technology Limited

What they do

The company operates through Haoxi Beijing, a wholly owned PRC subsidiary, from offices in Beijing's Chaoyang District. It is classified in the SEC's advertising agencies industry group (SIC 7311). Its structure includes Haoxi HK (Hong Kong) and a WFOE, Beijing Haoxi Health Technology Co., Limited. The filing excerpts provided do not describe the specific advertising products or services it sells.

Revenue drivers

• Advertising services (PRC operations) — The company is registered under the advertising agencies SIC code and conducts business through Haoxi Beijing in China; the filing excerpts provided do not break out revenue by product, service, or customer line.
• Segment or product detail — The excerpts provided do not disclose separate product lines, customer concentration, or segment-level revenue, so relative size of any individual offering cannot be stated.

Recent performance

Reported annual revenue fell from $28.2M in fiscal 2023 to $1.2M in fiscal 2024 and to $537,646 in fiscal 2025, per the XBRL data. Net income moved the other way, from $969,752 in 2023 to $1.3M in 2024 and $3.9M in 2025. Diluted EPS rose from $0.87 in 2023 to $1.06 in 2024 and $1.32 in 2025. Operating cash flow was negative each year shown, at -$872,132 in 2023, -$747,576 in 2024, and -$3.4M in 2025. At June 30, 2025, total assets were $21.6M, total liabilities $4.2M, and shareholder equity $17.4M.

Strategy

The filing excerpts provided do not contain a strategy section, so stated direction, planned investments, and priorities cannot be summarized from this material. The cover page confirms the company completed an IPO of 2,400,000 Class A Ordinary Shares at $4.00 per share, plus a 360,000-share over-allotment, for total gross proceeds of $11,040,000 (as stated in the excerpt). A share consolidation occurred on January 10, 2025, changing the par value of Class A and Class B ordinary shares to $0.0025. The excerpts identify no other strategic initiatives, acquisitions, or capital plans.

Risks

• Revenue collapse — Revenue fell from $28.2M in fiscal 2023 to $537,646 in fiscal 2025, a decline of more than 98% over two years, based on the XBRL data provided.
• Persistent negative operating cash flow — Operating cash flow was negative in each year shown, reaching -$3.4M in fiscal 2025, meaning operations consumed cash even as net income was positive.
• China operating and regulatory exposure — Operations are conducted by Haoxi Beijing in China and reported in RMB, exposing results to RMB/USD exchange-rate movements and PRC regulatory requirements, as noted in the filing's currency discussion.
• Dual-class share structure — As of June 30, 2025, 690,800 Class B ordinary shares carried 10 votes each while 2,205,795 Class A shares carried one vote each, concentrating voting power.

Outlook

The filing excerpts provided do not include management's forward-looking outlook or guidance, so no forward statements can be summarized. The most recent reported figures show sharply lower revenue alongside higher net income, and a $8.6M cash balance at June 30, 2025 against negative operating cash flow of $3.4M for the year.